Reiterated Zynerba Pharmaceuticals (ZYNE) Rating.
After Cantor Fitzgerald’s $11 TP was published on Thursday morning, Zynerba Pharmaceuticals (ZYNE) would indicate 130.13 % upside potential.
Ticker’s shares touched $4.78 during the last trading session after 2.80% change.Zynerba Pharmaceuticals, Inc. has volume of 761,142 shares. Since March 8, 2018 ZYNE has declined 47.62% and is downtrending. The stock underperformed the SP500 by 51.99%.
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)’s earnings release is awaited by WallStreet on March, 11, according to Faxor. Analysts forecast 11.67 % diference or $-0.67 from the $-0.6 EPS from 2018. Wall Street now predicts 42.55 % negative EPS growth despite Zynerba Pharmaceuticals, Inc. last quarter’s EPS of $-0.47.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.The firm is valued at $84.26 million. The firm focuses on developing and